PF-03084014 hydrobromide

C₂₇H₄₁F₂N₅O · HBr

570.56

329823821

NA.77

PF-03084014 inhibits the Notch signalling pathway. It contributes totumor suppression in breast, pancreatic carcinoma, hepatocellular carcinoma and progressive desmoid tumors. PF-03084014 in combination with dexamethasone elicits antileukemic effects in T-cell acute lymphoblastic leukemias (T-ALL).
PF-03084014 is a highly potent γ-secretase inhibitor that reduces Aβ production in vitro. PF-03084014 does not show a paradoxical increase in plasma Aβ at low concentrations in both preclinical species and humans.

This compound was developed by Pfizer for Neuroscience research. To learn more about Sigma′s partnership with Pfizer and view other authentic, high-quality Pfizer compounds, visit sigma.com/bsm-pfizer.

To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Sold for research purposes under agreement from Pfizer Inc.
Pfizer is a registered trademark of Pfizer, Inc.

100

≥98% (HPLC)

powder

Pfizer^®

white to beige

H₂O: 1 mg/mL, clear

Pfizer

room temp

FC1=C2C(CC[C@H](N[C@@H](CCC)C(NC3=CN(C(C)(C)CNCC(C)(C)C)C=N3)=O)C2)=CC(F)=C1.C

1S/C27H41F2N5O.CH4/c1-7-8-23(32-20-10-9-18-11-19(28)12-22(29)21(18)13-20)25(35)33-24-14-34(17-31-24)27(5,6)16-30-15-26(2,3)4;/h11-12,14,17,20,23,30,32H,7-10,13,15-16H2,1-6H3,(H,33,35);1H4/t20-,23-;/m0./s1

GLEYBLZDOTUZJH-WCRWPNQISA-N

5, 25 mg in glass bottle

GHS07

Warning

H315 - H319 - H335

P280 - P304 + P340 + P312 - P305 + P351 + P338 - P337 + P313

Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3

Respiratory system

13 - Non Combustible Solids

WGK 3